ATE533747T1 - Verfahren zur herstellung von tetrahydrochinolinderivaten - Google Patents

Verfahren zur herstellung von tetrahydrochinolinderivaten

Info

Publication number
ATE533747T1
ATE533747T1 AT07741046T AT07741046T ATE533747T1 AT E533747 T1 ATE533747 T1 AT E533747T1 AT 07741046 T AT07741046 T AT 07741046T AT 07741046 T AT07741046 T AT 07741046T AT E533747 T1 ATE533747 T1 AT E533747T1
Authority
AT
Austria
Prior art keywords
tetrahydrocinoline
derivatives
producing
tetrahydrocinoline derivatives
producing tetrahydrocinoline
Prior art date
Application number
AT07741046T
Other languages
English (en)
Inventor
Masaki Okamoto
Akira Sakuragi
Yoshikazu Mori
Takeshi Hamada
Hitoshi Kubota
Yoshinori Nakamura
Takanori Higashijima
Norimitsu Hayashi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE533747T1 publication Critical patent/ATE533747T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07741046T 2006-03-30 2007-03-29 Verfahren zur herstellung von tetrahydrochinolinderivaten ATE533747T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006092783 2006-03-30
JP2006322845 2006-11-30
PCT/JP2007/057610 WO2007116922A1 (en) 2006-03-30 2007-03-29 A process for preparing tetrahydroquinoline derivatives

Publications (1)

Publication Number Publication Date
ATE533747T1 true ATE533747T1 (de) 2011-12-15

Family

ID=38123770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07741046T ATE533747T1 (de) 2006-03-30 2007-03-29 Verfahren zur herstellung von tetrahydrochinolinderivaten

Country Status (10)

Country Link
US (1) US8084611B2 (de)
EP (2) EP2154132A1 (de)
JP (1) JP5275971B2 (de)
AR (1) AR060174A1 (de)
AT (1) ATE533747T1 (de)
ES (1) ES2374315T3 (de)
PE (1) PE20071150A1 (de)
TW (1) TW200808731A (de)
UY (1) UY30244A1 (de)
WO (1) WO2007116922A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2207775E (pt) 2007-11-05 2012-05-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
CN101878199B (zh) * 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1,2-二取代的-4-苄基氨基-吡咯烷衍生物
CN102020608B (zh) * 2010-09-17 2012-09-05 清华大学 喹啉化合物的制备方法
EP3180314B1 (de) 2014-08-12 2022-06-22 NewAmsterdam Pharma B.V. Verfahren zur herstellung von synthetischen zwischenprodukten zur herstellung von tetrahydroquinolin-derivaten
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
SG11202002300QA (en) 2017-10-02 2020-04-29 Arixa Pharmaceuticals Inc Aztreonam derivatives and uses thereof
EP3590927A1 (de) 2018-07-05 2020-01-08 Bayer Animal Health GmbH Neuartige verbindungen zur bekämpfung von arthropoden
WO2020072442A1 (en) 2018-10-01 2020-04-09 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
MX2021011026A (es) 2019-03-12 2021-10-13 Arixa Pharmaceuticals Inc Forma cristalina de un derivado de avibactam.
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
TWI843678B (zh) * 2019-06-18 2024-05-21 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
HUE067276T2 (hu) 2021-03-05 2024-10-28 Newamsterdam Pharma B V Obicetrapib demenciák kezelésére
CA3227153A1 (en) 2021-07-26 2023-02-02 Newamsterdam Pharma B.V. Treatment of his hyporesponders
EP4456872A1 (de) 2021-12-30 2024-11-06 NewAmsterdam Pharma B.V. Obicetrapib- und sglt2-inhibitorkombination
CN114516865B (zh) * 2022-03-09 2023-06-23 成都师范学院 一类D-π-A型有机共轭分子及其制备方法和应用
JP2025522311A (ja) 2022-05-25 2025-07-15 アカゲラ・メディスンズ,インコーポレイテッド 核酸を送達するための脂質ナノ粒子およびその使用方法
AR129814A1 (es) 2022-07-05 2024-10-02 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2024165395A1 (en) 2023-02-07 2024-08-15 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI82094C (fi) 1989-02-16 1997-09-09 Valmet Corp Anvaendning av en legering av ett metallpulver och en karbid eller nitrid innefattande belaeggningskomposition foer en i en pappersmaskin anvaendbar yankeecylinder
ATE147732T1 (de) 1989-03-08 1997-02-15 Merck Sharp & Dohme Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten
NZ234854A (en) 1989-08-11 1993-02-25 Ici Plc Quinoline derivatives, preparation, intermediates and pharmaceutical compositions thereof
JPH03161360A (ja) 1989-11-21 1991-07-11 Tdk Corp サーマルヘッド
JPH03216566A (ja) 1990-01-22 1991-09-24 Mitsubishi Electric Corp Ccdリニアイメージセンサのテスト装置
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
IE914573A1 (en) 1991-01-17 1992-07-29 Ici Plc Boron compounds
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な4−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5929281A (en) 1996-04-19 1999-07-27 Tosoh Corporation Process for producing heterocyclic aromatic amine or arylamine
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
EP1167521A1 (de) 2000-06-30 2002-01-02 Aventis Animal Nutrition S.A. Beschichtete enzymenthaltende Katalysator
AU2001279274A1 (en) 2000-07-25 2002-02-05 Digeo, Inc. Allowance account for interactive television system
JP2002053557A (ja) * 2000-08-14 2002-02-19 Japan Tobacco Inc アポリポ蛋白a−i産生促進薬
JP3440469B2 (ja) * 2000-08-18 2003-08-25 味の素株式会社 新規フェニルアラニン誘導体
SE0101161D0 (sv) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
PL366700A1 (en) 2001-04-30 2005-02-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
EP1318139A3 (de) 2001-12-07 2003-07-30 Solvias AG Verfahren zur Herstellung von 3-Aminokarbonsäuren und deren Estern
US6903233B2 (en) 2002-03-11 2005-06-07 Takasago International Corporation Process for producing optically active 3-halogenocarboxylic acid ester and 3-azidocarboxylic acid ester
KR100634195B1 (ko) 2002-08-30 2006-10-16 니뽄 다바코 산교 가부시키가이샤 디벤질아민 화합물 및 그 의약 용도
EP1556047A4 (de) 2002-10-04 2009-09-30 Millennium Pharm Inc Pgd2-rezeptor-antagonisten zur behandlungvon entz ndlichen erkrankungen
JP2004238322A (ja) 2003-02-05 2004-08-26 Sumika Fine Chemicals Co Ltd (r)−3−アミノペンタンニトリルメタンスルホン酸塩の製造方法
WO2004072041A1 (en) 2003-02-12 2004-08-26 Care X S.A. Tetrahydroquinolines as agonists of liver- x receptors
US7601842B2 (en) 2003-02-18 2009-10-13 Takasago International Corporation Method for producing an optically active tetrahydroquinoline
KR100729883B1 (ko) 2003-03-28 2007-06-18 화이자 프로덕츠 인코포레이티드 죽상경화증 및 비만증을 치료하기 위한 cetp억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체
JP2004339205A (ja) 2003-04-24 2004-12-02 Ajinomoto Co Inc 光学活性N−アリール−β−アミノ酸化合物の製造方法
US7145030B2 (en) 2003-04-24 2006-12-05 Ajinomoto Co., Inc. Production method for optically active N-aryl-β-amino acid compounds
ATE455088T1 (de) 2003-09-18 2010-01-15 Takasago Perfumery Co Ltd Asymmetrische reduktive aminierung von ketosäurederivaten zur herstellung von aminosäurederivaten
US20050239832A1 (en) * 2004-03-09 2005-10-27 Varghese John Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
CA2557010A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2005336083A (ja) 2004-05-26 2005-12-08 Sumitomo Chemical Co Ltd 芳香族アミノ化合物の製造方法
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии

Also Published As

Publication number Publication date
UY30244A1 (es) 2007-11-30
TW200808731A (en) 2008-02-16
ES2374315T3 (es) 2012-02-15
EP2007728B1 (de) 2011-11-16
US8084611B2 (en) 2011-12-27
AR060174A1 (es) 2008-05-28
JP5275971B2 (ja) 2013-08-28
WO2007116922A1 (en) 2007-10-18
JP2009532345A (ja) 2009-09-10
US20090292125A1 (en) 2009-11-26
PE20071150A1 (es) 2007-12-03
EP2154132A1 (de) 2010-02-17
EP2007728A1 (de) 2008-12-31

Similar Documents

Publication Publication Date Title
ATE533747T1 (de) Verfahren zur herstellung von tetrahydrochinolinderivaten
ATE455105T1 (de) Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
EP2170785A4 (de) Verfahren zur herstellung von hydrofluorolefinen
ATE408604T1 (de) Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
ATE480531T1 (de) Verfahren zur herstellung von benzopyran-2- olderivaten
ATE535568T1 (de) Verfahren zur herstellung von polyethylenzusammensetzungen
ATE516816T1 (de) Verfahren zur herstellung von impfstoffen
ATE529527T1 (de) Verfahren zur herstellung von alkoholen
ATE408609T1 (de) Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
ATE516362T1 (de) Verfahren zur herstellung von biodiesel
DE602007001585D1 (de) Verfahren zur herstellung von kunstlatex
ATE546436T1 (de) Verfahren zur herstellung von 2-amino-5- cyanobenzoesäurederivaten
DE602006015090D1 (de) Verfahren zur herstellung von gezielt durchlässigen laminaten
ATE518847T1 (de) Verfahren zur herstellung von betamimetika
ATE548345T1 (de) Verfahren zur herstellung von agomelatin
ATE523483T1 (de) Verfahren zur herstellung von betainen
ATE489015T1 (de) Verfahren zur herstellung von verschlüssen
DE602008006766D1 (de) Verfahren zur herstellung von würzwürfeln
ATE540585T1 (de) Verfahren zur herstellung von tomatenpaste
ATE554088T1 (de) Verfahren zur herstellung von pyridoä2,1- aüisochinolinderivaten
DE502006001281D1 (de) Verfahren zur herstellung substituierter biphenyle
ATE399157T1 (de) Verfahren zur herstellung von telmisartan
DE602007000239D1 (de) Verfahren zur Herstellung von hohlen Artikeln
ATE431868T1 (de) Verfahren zur herstellung laufmaschenfester textilien